Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pyxis Oncology, Inc. (PYXS : NSDQ)

• Company Description    Pyxis Oncology Inc. is a preclinical oncology company. It focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers. The company's product pipeline includes antibody drug conjugate and monoclonal antibody. Pyxis Oncology Inc. is based in CAMBRIDGE, Mass. Number of Employees: 44

• Price / Volume Information    Yesterday's Closing Price: $1.82 Daily Weekly Monthly 20 Day Moving Average: 775,544 shares Shares Outstanding: 62.02 (millions) Market Capitalization: $112.87 (millions) Beta: 1.14 52 Week High: $5.39 52 Week Low: $0.83 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 61.06% 58.23% 12 Week 59.65% 45.02% Year To Date 16.67% 6.46%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 321 HARRISON AVENUE - BOSTON,MA 02118 USA ph: 617-453-3596 fax: - ir@pyxisoncology.com http://www.pyxisoncology.com

• General Corporate Information    Officers Lara Sullivan - Chief Executive Officer; President and Director John Flavin - Chairman of the Board of Directors Pamela Connealy - Chief Financial Officer and Chief Operating Office Jitendra Wadhane - Chief Accounting Officer Thomas Civik - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 747324101 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/11/25 Share - Related Items Shares Outstanding: 62.02 Most Recent Split Date: (:1) Beta: 1.14 Market Capitalization: $112.87 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.32 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/11/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.29 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -3.45% vs. Previous Quarter: 14.29% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - -68.56 03/31/25 - -57.49 12/31/24 - -38.68 ROA 06/30/25 - -52.14 03/31/25 - -45.17 12/31/24 - -31.12 Current Ratio 06/30/25 - 5.65 03/31/25 - 7.75 12/31/24 - 7.49 Quick Ratio 06/30/25 - 5.65 03/31/25 - 7.75 12/31/24 - 7.49 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - -3,481.10 03/31/25 - - 12/31/24 - -492.35 Book Value 06/30/25 - 1.41 03/31/25 - 1.66 12/31/24 - 2.03 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - 0.00 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©